Enterprise has developed a pipeline of novel low molecular weight compounds with first-in-class and best-in-class potential – our most advanced drug is ETD001, which targets the ENaC ion channel in the airway epithelium, is expected to enter Phase 2 clinical trials mid-2022.
Low molecular weight mutant agnostic approaches
Enterprise is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases of high unmet medical need and commercial opportunity.
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.
Enterprise is developing muco-regulatory drugs that are expected to help respiratory patients by improving their ability to breath and reduce the number of lung infections they experience leading to a longer and more healthy life.
Sussex Innovation Centre,
University of Sussex,
Science Park Square,
Falmer, Brighton, BN1 9SB
info@enterprisetherapeutics.com
+44 (0)1273 234667
